Amelioration of Insulin, Leptin and Adiponectin Levels in Experimental Metabolic Syndrome Model by Some Drugs
| Autor: | N M Al Rasheed, H M Abdelkarem, F M Laila, M M Azza, M Al Rasheed Nawal, Y Bassiouni, H M Ali, H G Abeer |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Adiponectin Cholesterol business.industry Insulin medicine.medical_treatment Leptin nutritional and metabolic diseases Pharmaceutical Science 030204 cardiovascular system & hematology medicine.disease Metformin 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine High-density lipoprotein Endocrinology chemistry Internal medicine Hyperlipidemia medicine 030212 general & internal medicine Metabolic syndrome business medicine.drug |
| Zdroj: | Indian Journal of Pharmaceutical Sciences. 78 |
| ISSN: | 0250-474X |
| DOI: | 10.4172/pharmaceutical-sciences.1000173 |
| Popis: | A comparative study was planned to explore the modulating impact of metformin, lipitor or orlistat against the metabolic syndrome components, including hyperglycemia and hyperlipidemia. Also, the effects of these drugs on leptin and adiponectin as biomarkers of metabolic syndrome in a rat model were investigated for the first time. The administration of these drugs each alone to metabolic syndrome induced rats markedly ameliorated the increase in blood glucose, normalized the serum insulin and the high density lipoprotein cholesterol levels and reduced triglyceride, total cholesterol and low density lipoprotein cholesterol. The alterations in serum leptin and adiponectin levels in metabolic syndrome induced rats were significantly modulated by these drugs. Metformin was the most effective drug in modulating most of the studied parameters. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|